Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial (LEAP-AF)
Primary Purpose
Persistent Atrial Fibrillation, Catheter Ablation, Pulmonary Vein Isolation
Status
Recruiting
Phase
Phase 4
Locations
Japan
Study Type
Interventional
Intervention
Pulmonary vein isolation
Left posterior wall isolation
Sponsored by
About this trial
This is an interventional treatment trial for Persistent Atrial Fibrillation focused on measuring Persistent atrial fibrillation, Catheter ablation, Pulmonary vein isolation, Posterior wall isolation
Eligibility Criteria
Inclusion Criteria:
- Patients scheduled for first catheter ablation of persistent atrial fibrillation
- Patients without conversion to sinus rhythm within 30 days after antiarrhythmic drug administration
- Patients with persisting duration of atrial fibrillation less than 3 years
- Patients with left atrial diameter less than 50mm
- Patients who can be followed up for 18 months
- Patients with written informed consent
Exclusion Criteria:
- Patients who can not be received adequate anticoagulation therapy
- Patients with history of myocardial infarction within 6 months
- Patients with history of open heart surgery
- Patients scheduled for open heart surgery
- Patients with severe valvular heart disease
- Patients during pregnancy
- Patients with expected life expectancy less than 1 year due to malignancy or non-cardiovascular disease
- Patients considered unsuitable for study by the attending physician
Sites / Locations
- Kagawa Prefectural Central HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
PVI alone
PVI and PWI
Arm Description
Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
Outcomes
Primary Outcome Measures
Recurrence of atrial tachyarrhythmia after 90-day blanking period of catheter ablation
Recurrence of atrial tachyarrhythmia is defined atrial arrhythmia that needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.
Secondary Outcome Measures
Recurrence of atrial fibrillation or atrial tachycardia after 90-day blanking period of catheter ablation
Recurrence of atrial fibrillation or atrial tachycardia needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.
Recurrence of atrial fibrillation or atrial tachycardia within 90-day after catheter ablation
Recurrence of atrial fibrillation or atrial tachycardia needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.
Repeated ablation of atrial tachyarrhythmia
Recurrence of atrial fibrillation or atrial tachycardia after 90-day blanking period of repeated ablation
Atrial Fibrillation Quality of Life Questionnaire
Atrial Fibrillation Quality of Life Questionnaire
Complications of ablation procedure
Complications of ablation procedure includes death, cardiac tamponade, pericardial effusion, systemic embolism, symptomatic strokes, hematoma, A-V shunt, pericarditis, phrenic nerve paralysis, A-V block, procedure-related infections, heart failure, atrio-esophageal fistula, esophageal vagus nerve injury
Full Information
NCT ID
NCT04405258
First Posted
May 22, 2020
Last Updated
April 1, 2023
Sponsor
Institute for Clinical Effectiveness, Japan
1. Study Identification
Unique Protocol Identification Number
NCT04405258
Brief Title
Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial
Acronym
LEAP-AF
Official Title
Randomized Clinical Trial of Additional Left Atrial Posterior Wall Isolation for Persistent Atrial Fibrillation
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 8, 2020 (Actual)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute for Clinical Effectiveness, Japan
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose for this study is to determine whether left posterior wall isolation (PWI) in addition to pulmonary vein isolation (PVI) is effective as ablation strategy for persistent atrial fibrillation (AF).
Detailed Description
PVI is cornerstone of AF ablation. However, clinical outcome of only PVI in patients with persistent AF is insufficient due to AF substrate extending to left atrium. Strategy of catheter ablation for persistent AF is not established despite attempts of numerous left atrial substrate modifications. Additional PWI on PVI is one of expected effective strategies for persistent AF, because PW originated from common tissue of PV and is considered to play a part in AF trigger and maintenance. However, this strategy is also not established in the recent international consensus statement. Following two reasons are considered. One is the procedural difficulty in creating durable PWI, and another is the existence of patients who can recover by only PVI. The latest technology, ablation index, can create durable PVI, and may create durable PWI. Several reports suggested that PVI only strategy was sufficient in the patients with persistent AF who could maintain sinus rhythm after pharmacological or electrical cardioversion. Therefore, we planed this randomized clinical trial that compared between PVI alone and additional PWI on PVI using ablation index in the patients with persistent AF without pharmacological sinus rhythm conversion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Persistent Atrial Fibrillation, Catheter Ablation, Pulmonary Vein Isolation, Posterior Wall Isolation
Keywords
Persistent atrial fibrillation, Catheter ablation, Pulmonary vein isolation, Posterior wall isolation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
268 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PVI alone
Arm Type
Active Comparator
Arm Description
Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
Arm Title
PVI and PWI
Arm Type
Active Comparator
Arm Description
Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
Intervention Type
Procedure
Intervention Name(s)
Pulmonary vein isolation
Intervention Description
Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
Intervention Type
Procedure
Intervention Name(s)
Left posterior wall isolation
Intervention Description
Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
Primary Outcome Measure Information:
Title
Recurrence of atrial tachyarrhythmia after 90-day blanking period of catheter ablation
Description
Recurrence of atrial tachyarrhythmia is defined atrial arrhythmia that needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Recurrence of atrial fibrillation or atrial tachycardia after 90-day blanking period of catheter ablation
Description
Recurrence of atrial fibrillation or atrial tachycardia needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.
Time Frame
18 months
Title
Recurrence of atrial fibrillation or atrial tachycardia within 90-day after catheter ablation
Description
Recurrence of atrial fibrillation or atrial tachycardia needs admission, electrical cardioversion, and antiarrhythmic drug administration, and/or that persists more than 30 seconds.
Time Frame
90 days
Title
Repeated ablation of atrial tachyarrhythmia
Time Frame
18 months
Title
Recurrence of atrial fibrillation or atrial tachycardia after 90-day blanking period of repeated ablation
Time Frame
18 months
Title
Atrial Fibrillation Quality of Life Questionnaire
Description
Atrial Fibrillation Quality of Life Questionnaire
Time Frame
18 months
Title
Complications of ablation procedure
Description
Complications of ablation procedure includes death, cardiac tamponade, pericardial effusion, systemic embolism, symptomatic strokes, hematoma, A-V shunt, pericarditis, phrenic nerve paralysis, A-V block, procedure-related infections, heart failure, atrio-esophageal fistula, esophageal vagus nerve injury
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients scheduled for first catheter ablation of persistent atrial fibrillation
Patients without conversion to sinus rhythm within 30 days after antiarrhythmic drug administration
Patients with persisting duration of atrial fibrillation less than 3 years
Patients with left atrial diameter less than 50mm
Patients who can be followed up for 18 months
Patients with written informed consent
Exclusion Criteria:
Patients who can not be received adequate anticoagulation therapy
Patients with history of myocardial infarction within 6 months
Patients with history of open heart surgery
Patients scheduled for open heart surgery
Patients with severe valvular heart disease
Patients during pregnancy
Patients with expected life expectancy less than 1 year due to malignancy or non-cardiovascular disease
Patients considered unsuitable for study by the attending physician
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Keisuke Okawa, MD
Phone
+81-87-811-3333
Ext
5555
Email
k-ookawa@chp-kagawa.jp
First Name & Middle Initial & Last Name or Official Title & Degree
Masahiko Takahashi, MD
Phone
+81-87-811-3333
Ext
5558
Email
ma-takahashi@chp-kagawa.jp
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Keisuke Okawa, MD
Organizational Affiliation
Kagawa Prefectural Central Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kagawa Prefectural Central Hospital
City
Takamatsu
State/Province
Kagawa
ZIP/Postal Code
760-8557
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Keisuke Okawa, MD
Phone
+81-87-811-3333
Ext
5555
Email
k-ookawa@chp-kagawa.jp
First Name & Middle Initial & Last Name & Degree
Masahiko Takahashi, MD
Phone
+81-87-811-3333
Ext
5558
Email
ma-takahashi@chp-kagawa.jp
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
The data that support the findings of this study will be available from the data center upon reasonable request.
Learn more about this trial
Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial
We'll reach out to this number within 24 hrs